{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T05:06:56Z","timestamp":1774588016250,"version":"3.50.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100024028","name":"Hospital General Universitario Gregorio Mara\u00f1\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024028","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Farmacia Hospitalaria"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.farma.2025.08.007","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:15:18Z","timestamp":1758773718000},"page":"87-96","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Biochemical characteristics of inhaled antibiotics related to tolerability"],"prefix":"10.1016","volume":"50","author":[{"given":"Manuel","family":"V\u00e9lez-D\u00edaz-Pallar\u00e9s","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda \u00c1ngeles","family":"Parro-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hilario","family":"Mart\u00ednez-Barros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatriz","family":"Montero-Llorente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam","family":"Menacho-Rom\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"G\u00f3mez-Lozano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa Nieto","family":"Royo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis M\u00e1iz","family":"Carro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"\u00c1lvarez-D\u00edaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.farma.2025.08.007_bb0005","doi-asserted-by":"crossref","first-page":"598","DOI":"10.21037\/atm-20-3686","article-title":"Inhaled antibiotics during mechanical ventilation: why it will work","volume":"9","author":"Desgrouas","year":"2021","journal-title":"Ann Transl Med"},{"issue":"2","key":"10.1016\/j.farma.2025.08.007_bb0010","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s00134-015-4114-5","article-title":"Aerosol therapy in intensive and intermediate care units: prospective observation of 2808 critically ill patients","volume":"42","author":"Ehrmann","year":"2016","journal-title":"Intensive Care Med"},{"issue":"10","key":"10.1016\/j.farma.2025.08.007_bb0015","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S2213-2600(19)30185-7","article-title":"The efficacy and safety of inhaled antibiotics for the treatment of bronchiectasis in adults: a systematic review and meta-analysis","volume":"7","author":"Laska","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.farma.2025.08.007_bb0020","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.addr.2014.08.013","article-title":"Inhaled antimicrobial therapy \u2013 barriers to effective treatment","volume":"85","author":"Weers","year":"2015","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"10.1016\/j.farma.2025.08.007_bb0025","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13613-016-0140-x","article-title":"Characteristics of an ideal nebulized antibiotic for the treatment of pneumonia in the intubated patient","volume":"6","author":"Bassetti","year":"2016","journal-title":"Ann Intensive Care"},{"issue":"3","key":"10.1016\/j.farma.2025.08.007_bb0030","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1042\/cs0700301","article-title":"Chemical specificity of coughing in man","volume":"70","author":"Godden","year":"1986","journal-title":"Clin Sci (Lond)"},{"issue":"2","key":"10.1016\/j.farma.2025.08.007_bb0035","first-page":"211","article-title":"Alteration in osmolarity of inhaled aerosols causes bronchoconstriction and cough, but absence of a permeant anion causes cough alone","volume":"129","author":"Eschenbacher","year":"1984","journal-title":"Am Rev Respir Dis"},{"issue":"2","key":"10.1016\/j.farma.2025.08.007_bb0040","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3390\/antibiotics11020275","article-title":"Safety and efficacy of devices delivering inhaled antibiotics among adults with non-cystic fibrosis bronchiectasis: a systematic review and a network meta-analysis","volume":"11","author":"Tejada","year":"2022","journal-title":"Antibiotics (Basel)"},{"issue":"10","key":"10.1016\/j.farma.2025.08.007_bb0045","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.3390\/jcm12103577","article-title":"Efficacy and safety of dry powder antibiotics: a narrative review","volume":"12","author":"de la Rosa-Carrillo","year":"2023","journal-title":"J Clin Med"},{"issue":"3","key":"10.1016\/j.farma.2025.08.007_bb0050","doi-asserted-by":"crossref","first-page":"388","DOI":"10.4187\/respcare.02264","article-title":"Tobramycin inhalation powder in cystic fibrosis patients: response by age group","volume":"59","author":"Geller","year":"2014","journal-title":"Respir Care"},{"key":"10.1016\/j.farma.2025.08.007_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2022.102110","article-title":"Safety and tolerability of inhaled antibiotics in patients with bronchiectasis","volume":"72","author":"V\u00e9lez-D\u00edaz-Pallar\u00e9s","year":"2022","journal-title":"Pulm Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.farma.2025.08.007_bb0060","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.cmi.2017.03.018","article-title":"Key considerations on nebulization of antimicrobial agents to mechanically ventilated patients","volume":"23","author":"Rello","year":"2017","journal-title":"Clin Microbiol Infect"},{"issue":"2 Pt 2","key":"10.1016\/j.farma.2025.08.007_bb0065","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1016\/S0091-6749(99)70274-5","article-title":"Bronchoconstrictor additives in bronchodilator solutions","volume":"104","author":"Asmus","year":"1999","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.farma.2025.08.007_bb0070","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jcf.2003.12.005","article-title":"Effect of nebulized colistin sulphate and colistin sulphomethate on lung function in patients with cystic fibrosis: a pilot study","volume":"3","author":"Westerman","year":"2004","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.farma.2025.08.007_bb0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0149768","article-title":"Tolerability and pharmacokinetic evaluation of inhaled dry powder tobramycin free base in non-cystic fibrosis bronchiectasis patients","volume":"11","author":"Hoppentocht","year":"2016","journal-title":"PloS One"},{"issue":"1","key":"10.1016\/j.farma.2025.08.007_bb0080","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3390\/antibiotics5010002","article-title":"Cost reduction of inhaled tobramycin by use of preservative-free intravenous tobramycin given via inhalation","volume":"5","author":"Gauthier","year":"2016","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.farma.2025.08.007_bb0085","series-title":"Cayston (aztreonam for inhalation solution) prescribing information","author":"Gilead Sciences Inc.","year":"2025"},{"key":"10.1016\/j.farma.2025.08.007_bb0090","series-title":"AeroVanc (vancomycin hydrochloride inhalation powder)","author":"Savara Inc.","year":"2025"},{"issue":"8","key":"10.1016\/j.farma.2025.08.007_bb0095","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.3390\/antibiotics12081338","article-title":"Physicochemical characteristics of antimicrobials and practical recommendations for intravenous administration: a systematic review","volume":"12","author":"Borgonovo","year":"2023","journal-title":"Antibiotics (Basel)"},{"issue":"2","key":"10.1016\/j.farma.2025.08.007_bb0100","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1592\/phco.20.3.166.34783","article-title":"Aerosolized antimicrobial therapy in acutely ill patients","volume":"20","author":"Wood","year":"2000","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.farma.2025.08.007_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.opresp.2025.100460","article-title":"Short-term tolerance to inhaled antibiotics in patients with bronchial infection not associated with cystic fibrosis","volume":"7","author":"M\u00e1iz","year":"2025","journal-title":"Open Respir Arch"},{"issue":"10","key":"10.1016\/j.farma.2025.08.007_bb0110","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.arbres.2012.04.002","article-title":"Maintenance treatment with inhaled ampicillin in patients with cystic fibrosis and lung infection due to methicillin-sensitive Staphylococcus aureus","volume":"48","author":"M\u00e1iz","year":"2012","journal-title":"Arch Bronconeumol"},{"issue":"5","key":"10.1016\/j.farma.2025.08.007_bb0115","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ppul.20983","article-title":"Unorthodox long-term aerosolized ampicillin use for methicillin-susceptible Staphylococcus aureus lung infection in a cystic fibrosis patient","volume":"44","author":"M\u00e1iz","year":"2009","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.farma.2025.08.007_bb0120","article-title":"Prolonged treatment with inhaled ampicillin in children with non-cystic fibrosis bronchiectasis","volume":"25","author":"P\u00e9rez-Torres Lobato","year":"2020","journal-title":"Arch Bronconeumol"},{"issue":"10","key":"10.1016\/j.farma.2025.08.007_bb0125","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.arbres.2020.12.001","article-title":"Prolonged treatment with inhaled ampicillin in children with non-cystic fibrosis bronchiectasis","volume":"57","author":"P\u00e9rez-Torres Lobato","year":"2021","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.farma.2025.08.007_bb0130","series-title":"GRAS substances (SCOGS) database","author":"U.S. Food and Drug Administration","year":"2025"},{"issue":"1\u20132","key":"10.1016\/j.farma.2025.08.007_bb0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2010.03.017","article-title":"Formulation strategy and use of excipients in pulmonary drug delivery","volume":"392","author":"Pilcer","year":"2010","journal-title":"Int J Pharm"},{"issue":"6","key":"10.1016\/j.farma.2025.08.007_bb0140","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1164\/ajrccm\/141.6.1400","article-title":"Effect of inhaled preservatives on asthmatic subjects. I. Sodium metabisulfite","volume":"141","author":"Wright","year":"1990","journal-title":"Am Rev Respir Dis"},{"issue":"18","key":"10.1016\/j.farma.2025.08.007_bb0145","doi-asserted-by":"crossref","first-page":"4096","DOI":"10.1111\/bph.15197","article-title":"Cough as an adverse effect on inhalation pharmaceutical products","volume":"177","author":"Chang","year":"2020","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.farma.2025.08.007_bb0150","series-title":"NIOSH pocket guide to chemical hazards","article-title":"Phenol","author":"National Institute for Occupational Safety and Health (NIOSH)","year":"2007"},{"issue":"1","key":"10.1016\/j.farma.2025.08.007_bb0155","doi-asserted-by":"crossref","first-page":"T29","DOI":"10.1016\/j.farma.2023.09.006","article-title":"Caracterizaci\u00f3n y resultados del uso de voriconazol nebulizado en un entorno real: un estudio observacional unic\u00e9ntrico","volume":"48","author":"Larrosa-Garc\u00eda","year":"2024","journal-title":"Farm Hosp"},{"issue":"2","key":"10.1016\/j.farma.2025.08.007_bb0160","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0378-5173(99)00252-5","article-title":"Inhalation of tobramycin in cystic fibrosis. Part 2: optimization of the tobramycin solution for a jet and an ultrasonic nebulizer","volume":"189","author":"Le Brun","year":"1999","journal-title":"Int J Pharm"},{"key":"10.1016\/j.farma.2025.08.007_bb0165","series-title":"Targeting chronic inflammatory lung diseases using advanced drug delivery systems","first-page":"57","article-title":"Novel drug delivery systems and significance in respiratory diseases","author":"Mishra","year":"2020"}],"container-title":["Farmacia Hospitalaria"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634325001205?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634325001205?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T03:00:18Z","timestamp":1774580418000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1130634325001205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1130634325001205"],"URL":"https:\/\/doi.org\/10.1016\/j.farma.2025.08.007","relation":{},"ISSN":["1130-6343"],"issn-type":[{"value":"1130-6343","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biochemical characteristics of inhaled antibiotics related to tolerability","name":"articletitle","label":"Article Title"},{"value":"Farmacia Hospitalaria","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2025.08.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Espa\u00f1a, S.L.U. on behalf of Sociedad Espa\u00f1ola de Farmacia Hospitalaria (S.E.F.H).","name":"copyright","label":"Copyright"}]}}